SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 424B4 - Prospectus [Rule 424(b)(4)]:
SEC Accession No. 0001047469-17-000398
Filing Date
2017-01-27
Accepted
2017-01-27 16:50:38
Documents
12

Document Format Files

Seq Description Document Type Size
1 424B4 a2230784z424b4.htm 424B4 2562515
2 G1000611.JPG g1000611.jpg GRAPHIC 13093
3 G72672.JPG g72672.jpg GRAPHIC 63279
4 G884698.JPG g884698.jpg GRAPHIC 75338
5 G1044131.JPG g1044131.jpg GRAPHIC 35512
6 G753014.JPG g753014.jpg GRAPHIC 45415
7 G1026852.JPG g1026852.jpg GRAPHIC 87531
8 G639644.JPG g639644.jpg GRAPHIC 81322
9 G475797.JPG g475797.jpg GRAPHIC 82029
10 G600598.JPG g600598.jpg GRAPHIC 93362
11 G852019.JPG g852019.jpg GRAPHIC 58963
12 G379686.JPG g379686.jpg GRAPHIC 98739
  Complete submission text file 0001047469-17-000398.txt   3576816
Mailing Address 1030 MASSACHUSETTS AVE. CAMBRIDGE MA 02138
Business Address 1030 MASSACHUSETTS AVE. CAMBRIDGE MA 02138 857-259-3840
Jounce Therapeutics, Inc. (Filer) CIK: 0001640455 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 424B4 | Act: 33 | File No.: 333-215372 | Film No.: 17554394
SIC: 2836 Biological Products, (No Diagnostic Substances)